Lenalidomide in cancer cachexia: a randomized trial of an anticancer drug applied for anti‐cachexia
Abstract Background Cancer cachexia (CC) impacts quality of life, physical function, anticancer treatment response, and survival. Inflammation is a prominent pathomechanism of CC. This small‐scale study sets out to investigate the immunomodulatory drug lenalidomide in inflammatory CC in a randomized...
Saved in:
Main Authors: | David Blum (Author), Caroline Hertler (Author), Rolf Oberholzer (Author), Susanne deWolf‐Linder (Author), Markus Joerger (Author), Christoph Driessen (Author), Florian Strasser (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natural ghrelin in advanced cancer patients with cachexia, a case series
by: David Blum, et al.
Published: (2021) -
Inflammation in Cachexia
by: M. Seelaender, et al.
Published: (2015) -
Oral Equilibrium in Cachexia
by: Deepthi Darwin, et al.
Published: (2021) -
Cachexia and advanced dementia
by: Cecilia Minaglia, et al.
Published: (2019) -
The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model
by: Luping Yuan, et al.
Published: (2023)